Harrison, Ph.D., Danielle E. Bear, M.Res., Ella Segaran, M.Sc., Richard Beale, M.B., B.S., Geoff Bellingan, M.D., Richard Leonard, M.B., B.Chir., Michael G. Mythen, M.D., and Kathryn M. Rowan, Ph.D. The interpretation of published meta-analyses of trials comparing dietary support through the parenteral path versus the enteral path in critically ill sufferers1-3 is complicated by little sample sizes, variable quality, selection bias, lack of standardized definitions, and interventions that combine multiple elements of nutritional support .Kinetics of Minimal Residual Disease The kinetics of PML-RARA transcript reduction after induction and consolidation therapy were assessed in 63 unselected patients. There have been no significant variations between your two groups .).001).001).001). In 1 of the 12 patients with a prolonged QTc interval, arsenic trioxide was discontinued, and the individual went off protocol. Info on nonhematologic toxic results is shown in Desk S3 in the Supplementary Appendix. Discussion This study implies that a combined mix of ATRA and arsenic trioxide given for induction and consolidation therapy is at least not inferior and is possibly more advanced than standard ATRA and anthracycline-based chemotherapy for adults with low-to-intermediate-risk APL.